Basis: Current FMP quote-based enterprise value / four-quarter revenue. Source: stored company filings and market data; unavailable inputs remain N/A.
The EV/Sales ratio is N/A as of 2026-10-06T19:56:15.917Z.
Calculation as of: 2026-10-06T19:56:15.917Z.
Quote observation: 2026-10-06T19:55:23.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 979ff17a100a324a490b4ea8bab969f4c23ca35a684dd985742eca9c7cd70937
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
EV/SALES RATIO
N/A
Market Cap
$627.54M
EV/Sales Ratio
6.75x
TTM Avg
4.65x
3Y Avg
3.50x
5Y Avg
3.58x
Market Cap
$597.55M
EV/Sales Ratio
2.35x
TTM Avg
3.07x
3Y Avg
3.40x
5Y Avg
3.86x
Market Cap
$593.45M
EV/Sales Ratio
1.69x
TTM Avg
1.55x
3Y Avg
1.11x
5Y Avg
1.54x
Market Cap
$632.02M
EV/Sales Ratio
3.59x
TTM Avg
5.69x
3Y Avg
10.23x
5Y Avg
9.87x
Market Cap
$636.68M
EV/Sales Ratio
172.28x
TTM Avg
136.19x
3Y Avg
307.18x
5Y Avg
307.18x
Market Cap
$582.09M
EV/Sales Ratio
1.74x
TTM Avg
1.86x
3Y Avg
1.97x
5Y Avg
1.94x
| NAME | MARKET CAP | EV/SALES RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Climb Bio, Inc. (CLYM) | $611.00M | N/A | N/A | N/A | N/A |
| OmniAb, Inc. (OABI)vs › | $622.66M | 16.06x | 10.41x | 12.28x | 16.01x |
| SOPHiA GENETICS S.A. (SOPH)vs › | $627.54M | 6.75x | 4.65x | 3.50x | 3.58x |
| Ironwood Pharmaceuticals, Inc. (IRWD)vs › | $597.55M | 2.35x | 3.07x | 3.40x | 3.86x |
| AngioDynamics, Inc. (ANGO)vs › | $593.45M | 1.69x | 1.55x | 1.11x | 1.54x |
| Zevra Therapeutics, Inc. (ZVRA)vs › | $632.02M | 3.59x | 5.69x | 10.23x | 9.87x |
| Prime Medicine, Inc. (PRME)vs › | $636.68M | 172.28x | 136.19x | 307.18x | 307.18x |
| Aura Biosciences, Inc. (AURA)vs › | $637.69M | N/A | N/A | N/A | N/A |
| Fulgent Genetics, Inc. (FLGT)vs › | $582.09M | 1.74x | 1.86x | 1.97x | 1.94x |
| OrthoPediatrics Corp. (KIDS)vs › | $582.20M | 2.60x | 2.20x | 3.12x | 5.45x |
Enterprise Value (EV) = Market Cap + Total Debt - Cash
Sales = Total Revenue (TTM)
EV/Sales is commonly used because:
Note: EV/Sales does not include margin, debt maturity, cash conversion, or growth durability by itself.
EV/Sales = Enterprise Value / Revenue (TTM)
Enterprise value to sales compares total company value to revenue, useful across capital structures and for unprofitable companies.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
